Cutaneous melanoma: Diagnosis, Treatment and Postoperative Follow-up
Authors:
I. Krajsová
Authors place of work:
Dermatovenerologická klinika VFN a 1. LF UK, Praha
přednosta prof. MUDr. Jiří Štork, CSc.
Published in the journal:
Čes-slov Derm, 87, 2012, No. 5, p. 163-174
Category:
Reviews (Continuing Medical Education)
Summary
In the forties to the eighties began to dramatically increase the incidence of cutaneous melanoma. The increased frequency was so high that the tumor came to the forefront of professional and public interest. Therefore, it significantly improved clinical diagnostics and increased detection of early melanomas prognostically favorable. Currently the melanomas of stage I represent more than 60% of all melanomas in the Czech Republic. Based on the results of randomized prospective studies the recommendations of standard surgical procedures including the sentinel lymph node examination were elaborated. Development of tumor immunology and deeper insights into the biology of melanoma allow the introduction of new therapies. The last two years have been published results of studies with ipilimumab and vemurafenib, drugs, which open a new era in the treatment of metastatic melanoma.
There are no unified recommendations for the monitoring and investigation of patients after advanced melanoma surgery. The frequency of clinical check-ups and type of staging examinations differs significantly in individual countries. The determining factors for the selection of intervals and monitoring methods in asymptomatic patients after melanoma surgery should be the basic histopathological and clinical prognostic tumor characteristics.
Key words:
melanoma – diagnosis – treatment- postoperative follow-up
Zdroje
1. ASCIERTO, P. A., GRIMALDI, A. M., CURIT, B., FLAHERTY, K. et al. Future perspectives in melanoma research. Meeting report from the Melanoma research: a bridge from Naples to the World. Napoli, December 5th–6th 2011. J. Translational. Medicine, 2012, May, 10, doi:10.1186/1479-5876-10-83
2. BOLAND, G. M., GERSHENWALD, J. E. Sentinel lymph node biopsy in melanoma. Cancer J., 2012, 18, 2, p. 185–191.
3. BICHAKJIAN, C. K., HALPERN, A. C., JOHNSON, M. T., HOOT, F. A., GRICHNIK, J. M. et al. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol., 2011, 65, p. 1032–1047.
4. DUMMER, R., HAUSCHILD, A., GUGGENHEIM, M., JOST, L., PENTHEROUDAKIS, G. Melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol., 2010, Suppl 5, 21, p. 194–197.
5. EGGERMONT, A. M. M., TESTORI, A., MAIO, M., ROBERT, C. Anti-CTLA-4 antibody. Adjuvant therapy in melanoma. Semin. Oncol., 2010, 37, 5, p. 455–459.
6. FLAHERTY, T. K., ROBERT, C., HERSEY, P. et al. Improved survival with MEK inhibition of BRAF mutated melanoma. N. Engl. J. Med., 2012, Jun, p. 1–8.
7. FLAHERTY, T. K., SOSMAN, A. J., ATKINS, M. B. New options and new questions: How to select and sequence therapies for patients with metastatic melanoma. Am. Soc. Clin. Oncol., 2012, 1092-9118/10/1-10, p. 524–530.
8. FRANCKEN, A. B., ACCORTT, N. A., SHAW, A. M., COMAN, M. H., WIENER, M. et al. Follow-up schedules after treatment for malignant melanoma. Br. J. Surg., 2008, Nov, 95, 11, p. 1401–1407.
9. FRANCKEN, A. B., SHAW, H. M., SOONG, S. J., THOMPSON, J. F. Detection of first relapse in cutaneous melanoma patients: implication for the formulation of evidence-based follow-up guidelines. Ann. Surg. Oncol., 2007, Jun, 14, 6, p. 1924–1933.
10. FORSCHNER, A., EIGENTLER, T. K., PFLUGPFELDER, A., GARBE, C. et al. Melanoma staging: facts and controversies. Clin. Dermatol., 2010, May-Jun, 28, 3, p. 275–280.
11. HENEBERG, P. Pokroky v klinické léčbě zhoubného melanomu:inhibice kinázy BRAF. Klinická onkologie, 2011, 24, 4, s. 256 až 264.
12. HODI, F. S., O’DAY, S. J., MCDERMOTT, D. F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363, p. 711–723.
13. HOLTERHUES, C., VAN DE POLL-FRANSE, L.V., DEVRIES, E., NEUMNN, H. A., NISTEN, T. E. Melanoma patients receive more follow-up care than current guideline recommendations: a study of 546 paitens from general Dutch population. J. Uer. Acad. Dermaol. Venereol., 2011, Oct 31, doi:10.1111/j.1468-3088.
14. CHAPMAN, P. B., HASCHILD, A., ROBERT, C. et al. Improved survival with vemurafenib in melanoma with BRAF V 600E mutation. N. Engl. J. Med., 2011, 364, p. 2507–2516.
15. KANZLER, M. H., MRAZ-GERNHARD, S. Primary cutaneous melanoma and its precursor lesions: Diagnostic and therapeutic overview. J. Am. Acad. Dermatol., 2001, 45, p. 260–276.
16. KRAJSOVÁ, I., VYZULA, R., LAKOMÝ, R., KUBALA, E., ŠTASTNÝ, M., MELICHAR, B. Imunoterapie přináší nové typy klinické odpovědi: ipilimumab u pacientů s metastatickým melanomem. Farmakoterapie, 2012, 8, 2, s. 133–252.
17. KUNISHIGE, J. H., BRODLAND, D. G., ZITELLI, J. A. Surgical margins for melanoma in situ. J. Am. Acad. Dermatol., March 2012, 66, 3, p. 438–444.
18. LEE, B., MUKHI, N., LIU, D. Current managemnt and novel agents for malignant melanoma. J. Hem. Oncol., 2012, 5, 3, p. 1–7.
19. LEMECH, C. H., ARKENAU, H. T. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin. Med. Insights. Oncol., 2012, 6, p. 53–66.
20. McMASTERS, K. M., WONG, S. L., EDWARDS, M. J. et al. Frequency of nonsentinel pmph node metastasis in melanoma. Ann. Surg. Oncol., 2002, 9, 2, p. 137–141.
21. MEYERS, M. O., YEH, J. J., FRANK, J., LONG, P., DEAL, A. M., OLLILA, D. W. Method of detecion of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow- -up staging. Ann. Surg. Oncol., 2009, Apr, 16, 4, p. 941–947.
22. MOCELLIN, S., PASQUALI, S., ROSSIN, C., NITTIN, D. Interferon alfa adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J. Natl. Cancer Inst., 2010, 102, p. 493–501.
23. MORTON, D. L., THOMPSON, J. F., COCHRAN, A. J. et al. Sentinel node biopsy or nodal observation in melanoma. N. Engl. J. Med., 2006, 355, 13, p. 1307–1317.
24. OKUYAMA, S., GONZALES, R., LEWIS, D. K. Pegylated interferon alfa-2b as adjuvant treatment of stage III malignant melanoma: an evidence based review. Core Evidence, 2010, 5, p. 39–48.
25. PATEL, S. P., WOODMAN, S. E. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des. Devel. Ther., 2011, 5, p. 489–495.
26. PHAN, G. Q., MESSINA, J. L., SONDAK, V. K., ZAGER, S. J. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control, 2009, 16, 3, p. 234–239.
27. POO-HWU, W. J., ARIYAN, S., LAMB, L., PAPAC, R., ZELTERMAN, D., HU, G. L., BROWN, J., FISCHER, D., BOLOGNIA, J., BUZAID, A. C. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer, 1999, 86, 11, p. 2252–2258.
28. ROBERT, C., THOMAS, L., BONDARENKO, I. et al. Ipilimumab plus Dacarbazin for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364, p. 2517–2526.
29. ROMANO, E., SCORDO, M., DUSZA, S. W., COIT, D. G., CHAPMAN, P. B. Site and timing of first relaps in stage III melanoma patients: implication for follow-up guidelines. J. Clin. Oncol., 2010, Jun 20, 28, 18, p. 3042–3047.
30. SCHEIER, B., AMARIA, R., LEWIS, K., GONZALES, R. Novel therapies in melanoma. Immunotherapy, 2011, 3, 12, p. 1461–1469.
31. SIEGEL, R., NAIHADHM, D., JERNAL, H. Cancer statistics 2012, CA Cancer J. Clin., 2012, 62, p. 10–29.
32. THOMPSON, J. A., HAMID, O. ET AL. Ipilimumab in tretament-naive and previously treated patientts with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J. Immunother., 2012, 35, 1, p. 73–77.
33. TURNER, M., BELL, J. L. K., MORTON, L. R., THOMPSON, J. F. et al. Optimizing the frequency of follow-up visits in patients treated for localised primary cutanous melanoma. J. Clin. Oncol., 2011, Vol. 29, 35, p. 4641–4646.
34. VAN AKKOOI, A. C., SPATZ, A., EGGERMONT, A. M., MIHM, M., COOK, M. G. Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. Eur. J. Cancer, 2009, 45, 16, p. 2736–2742.
35. VAN DER PLOEG, A. P., VAN AKKOOI, A. C., SCHMITZ, P. I., KOLJENOVIC, S., VERHOEF, C., EGGERMONT, A. M. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. Eur. J. Cancer, 2010, 46, 13, p. 2414–2421.
36. VAN der PLOEG, A. P., VAN AKKOOI, A. C., RUTKOWSKI, P., NOWECKI, Z. I., MICHEJ, W., MITRA, A., NEWTON-BISHOP, J. A., COOK, M., VAN DER PLOEG, I. M., NIEWEG, O. E., VAN DEN HOUT, M. F., VAN LEEUWEN, P. A., VOIT, C. A., CATALDO, F., TESTORI, A., ROBERT, C., HOEKSTRA, H. J., VERHOEF, C., SPATZ, A., EGGERMONT, A. M. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J. Clin. Oncol., 2011, 29, 16, p. 2206–2214.
37. WOLCHOK, J. D., HOOS, A., O’DAY, S. et al. Guidelines for the evaluation of imine therapy aktivity in solid tumors: Immune-related response kriteria. Clin. Cancer Res., 2009, 15, p. 7412–7420.
38. XING, Y., CROMWELL, K. D., CORMIER, J. N. Review of diagnostic imaging modalities for the surveillance of melanoma patients. Dermatol. Res. Pract., 2012, doi:10.1155/2012/941921.
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2012 Číslo 5
Najčítanejšie v tomto čísle
- Cutaneous melanoma: Diagnosis, Treatment and Postoperative Follow-up
- Sarcoidosis: a Case with Less Common Clinical Manifestations
- Metastatic Melanoma Successfully Treated with Ipilimumab
- Photodynamic Antiseptic Effect of Photoactive Nanofibers in the Treatment of Leg Ulcers